206-838-5110 ext. 102 general@etubics.com

SEATTLE (September 22, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines, announced today that it was awarded two contracts from the National Cancer Institute (NCI): $1,499,001 to manufacture Etubics’ CEA product for colon cancer immunotherapy; and $199,988 to evaluate and manufacture Etubics’ HER2/neu product for breast cancer immunotherapy.

Etubics has completed a Phase I/IIa clinical trial with an immunotherapeutic to treat advanced colorectal cancer. The CEA product contract will allow Etubics to manufacture their patented CEA product for colon cancer immunotherapy, allowing the company to move into Phase IIb trials with an expanded group of patients. The NCI contract will provide sufficient funding for the entire manufacturing project. Etubics Phase I/IIa colorectal cancer trial, as well as pre-clinical work, has been funded entirely through grants from the NCI.

The breast cancer contract will allow Etubics’ to evaluate and manufacture its patented HER2/neu product for breast cancer immunotherapy, which will be utilized in an upcoming Phase I/II trial. The company hopes to show that their technology is effective in stimulating both a cell-mediated immune and an antibody response against breast cancer. Pre-clinical studies showed that treatment with the Etubics Platform reduced tumor volume in established HER2/neu positive tumors and prevented tumor implantation and progression and was recently published in Nature’s Cancer Gene Therapy (Abstract can be found at: http://www.nature.com/cgt/journal/v18/n5/full/cgt201082a.html). This NCI contract will support 85% of the evaluation and manufacturing project. Etubics HER2/neu pre-clinical work has been funded entirely through grants from the NCI.

Etubics is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus vector delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform.

About Etubics

Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .

www.etubics.com

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

###

Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 ines@etubics.com

Click to Download PDF